April 27, 2018
Understanding Cancer Progression and Metastasis
“Cancer progression” is the process by which this disease goes from bad to worse. Molecularly, the course of cancer progression is set by accumulation of mutations in genes, resulting in activation and inactivation of oncogenes and suppressor genes. At the cellular and tissue level, advanced cancers evade the immune system, stimulate the development of a ...
LEARN MORE
April 20, 2018
Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions
NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of patient genotype-relevant ...
LEARN MORE
April 13, 2018
The Establishment and Characterization of PDX Models
Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo oncology studies than ...
LEARN MORE
April 5, 2018
The Limits of In Vitro and Ex Vivo Immuno-Oncology Assays
Studying the immune system in vivo can be challenging, and in vitro and ex vivo assays are often used to reduce system ...
LEARN MORE
March 22, 2018
Are There Are Five Types of Diabetes?
New research suggests that there are five types of diabetes, rather than simply Type 1 or Type 2. Understanding ...
LEARN MORE
March 19, 2018
Targeting Myeloid Derived Suppressor Cells in Immuno-Oncology
Immune checkpoint inhibitors (ICIs) have dramatically changed the therapeutic approach to cancer, with antibodies ...
LEARN MORE
March 13, 2018
ICOS: Immunostimulatory or Immunosuppressive Target?
The rise of immunotherapy has brought many new targets to the forefront of oncology drug development. One promising new avenue of investigation is ICOS, an immune checkpoint expressed on activated T cells, which has opposing functions in sustaining T cell activation and in Treg suppressive activity.
LEARN MORE
March 7, 2018
New Technique Opens Novel Approaches to Insulin Resistance
A newly-described technique could open multiple lines of investigation into the pathophysiology and treatment of ...
LEARN MORE
March 1, 2018
Using T Cells in Immuno-Oncology
Immuno-oncology drug development challenges researchers to model the interaction between novel immunotherapy agents, ...
LEARN MORE
February 27, 2018
CAR-T Cell Therapy: Use Earlier for Better Results
CAR-T cell therapies are still in their infancy as clinical oncology treatments, with the first agent approved just 6 ...
LEARN MORE
February 22, 2018
Tumor Infiltrating Lymphocytes: Conflicting Approaches in Immuno-Oncology
Today’s new frontier in cancer treatment is in fact a very, very old frontier indeed: tumor infiltrating lymphocytes (TILs). New as they seem, TILs were first observed over 150 years ago by Rudolf Virchow, the father of modern pathology. It was a time when disease was considered to be the result of imbalanced bodily humors and his use of a microscope was a ...
LEARN MORE
February 20, 2018
How to Assess CAR-T Cell Therapies Preclinically
Chimeric antigen receptor (CAR)-T cell therapies are a new and novel immuno-oncology treatment modality, only recently ...
LEARN MORE
February 16, 2018
3 Key Uses for Humanized Mouse Models
We’ve been focusing on humanized mouse models recently on our blog, from evolution of immunodeficient host mice through ...
LEARN MORE
February 9, 2018
X Chromosome Inactivation: New Hypothesis for Lupus Gender Disparity
It’s widely accepted that lupus occurs more often in women than men, with many studies over the years trying to ...
LEARN MORE
January 30, 2018
Humanized Mouse Model Head to Head: hPBMC vs hCD34+
The future of cancer treatment is often considered to be combination regimens (dual immunotherapeutics or ...
LEARN MORE
